Stockreport

Regeneron: A Buy On Dupixent And Pipeline [Seeking Alpha]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Summary Regeneron ( REGN ) is priced nicely for buyers, given its profit growth and clinical pipeline of potential new drugs. Regeneron is a large cap ($38.8 billio [Read more]